SCHEMBL1499343

SCHEMBL1499343

CCN(CC)CCCNC(=O)c1cccc(Nc2cccc(C=Cc3ccccn3)c2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ IGF1R P08069 1/20 0.45
▸ CDK4 P11802 1/20 0.43
▸ CDK2 P24941 1/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ ATG4B Q9Y4P1 1/20 0.41
▸ HCRTR1 O43613 1/20 0.41
▸ BCHE P06276 1/20 0.41
▸ TP53 P04637 1/20 0.40
▸ PIP5K1C O60331 1/20 0.40
▸ PIK3CA P42336 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ PRMT5 O14744 1/20 0.39
▸ WDR77 Q9BQA1 1/20 0.39
▸ RAD52 P43351 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1499341 1.00 KMT2A (0.45) KMT2AMEN1NPC1RAB9AIGF1R
SCHEMBL1499327 0.94 IGF1R (0.44) KMT2AMEN1IGF1RCDK4CDK2
SCHEMBL1499328 0.94 IGF1R (0.44) KMT2AMEN1IGF1RCDK4CDK2
SCHEMBL1499529 0.94 IGF1R (0.44) KMT2AMEN1NPC1RAB9AIGF1R
SCHEMBL1499526 0.94 IGF1R (0.44) KMT2AMEN1NPC1RAB9AIGF1R
SCHEMBL12966945 0.89 BCHE (0.47) KMT2AMEN1IGF1RBCHESMN1; SMN2
SCHEMBL1499549 0.88 IGF1R (0.45) KMT2AMEN1IGF1RCDK4CDK2
SCHEMBL1499548 0.88 IGF1R (0.45) KMT2AMEN1IGF1RCDK4CDK2
SCHEMBL1499521 0.85 HDAC6 (0.50) KMT2AMEN1IGF1RTP53SMN1; SMN2
SCHEMBL1499516 0.85 HDAC6 (0.50) KMT2AMEN1IGF1RTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604063-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) 2013-12-10 — — US claimed
JP-2011509280-A — — 2011-03-24 — — JP claimed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 — — US claimed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 — — EP claimed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 — — WO claimed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 — — WO claimed
EP-3536691-B1 CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2022-10-05 — — EP disclosed
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 — — EP disclosed
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-05-19 — — US disclosed
EP-3536691-A1 CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) 2019-09-11 — — EP disclosed
US-20190022037-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-01-24 — — US disclosed
US-10130595-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) 2018-11-20 — — US disclosed
US-20160166519-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CT NATIONALE DE RECH SCIENT (FR) 2016-06-16 — — US disclosed
US-9233931-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) 2016-01-12 — — US disclosed
US-20140155436-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) 2014-06-05 — — US disclosed
US-8604063-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) 2013-12-10 — — US disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 — — US disclosed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 — — EP disclosed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 — — WO disclosed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10130595-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies RBM17, RBM22, SF3B1 KMT2A 3187/4885MEN1 834/4885NPC1 769/4885
US-20160166519-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, RBM22, SF3B1 KMT2A 3187/4885MEN1 834/4885NPC1 769/4885
US-20190022037-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, RBM22, PRPF40A KMT2A 4141/4885MEN1 1147/4885NPC1 589/4885
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies RBM17, RBM22, PRPF40A KMT2A 4141/4885MEN1 1147/4885NPC1 589/4885
US-20140155436-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, SF3B5, SF3B1 KMT2A 2724/4885MEN1 1067/4885NPC1 922/4885
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, SF3B5, SF3B1 KMT2A 2724/4885MEN1 1067/4885NPC1 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback